文献速递炎症性肠病

克罗恩病肠道损伤与残疾:Lémann指数与IBD残疾指数的前瞻性研究

Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the Lémann Index and Inflammatory Bowel Disease Disability Index.
PubMed 文献 · Aliment Pharmacol Ther · 2020-03-27

平均Lémann指数为11.9±14.1,平均IBD残疾指数为28.8±6.3,两指数间无相关性(P=0.15)。早期(病程前2年)使用抗TNF与较低的肠道损伤评分相关(P=0.015)。

要点

  • Lémann指数与IBD残疾指数在克罗恩病中无相关性(P=0.15)。
  • 早期(病程前2年)使用抗TNF与较低肠道损伤评分相关(P=0.015)。
  • 肛周病变、疾病活动度与抗TNF暴露与高肠道损伤及高残疾评分相关。

核心结论

  • 早期引入抗TNF治疗与较低的肠道损伤评分相关。
  • Lémann指数与IBD残疾指数之间未观察到相关性(P=0.15)。

研究设计与样本

  • 前瞻性研究,在三级转诊中心连续纳入所有克罗恩病门诊患者。

主要发现

  • 平均Lémann指数(±SD)为11.9±14.1,范围0至72.5分。
  • 平均IBD残疾指数为28.8±6.3,范围0至71分。
  • 高肠道损伤评分相关因素:疾病病程、肛周位置、既往肠切除、临床和生物学疾病活动、免疫抑制剂暴露、抗TNF暴露(P<0.005)。
  • 抗TNF暴露患者中,病程前2年内暴露者Lémann指数更低(P=0.015)。
  • 高残疾评分相关因素:女性、肛周位置、肠外表现、临床和生物学疾病活动、抗TNF暴露(P<0.005)。

临床怎么用

  • 在克罗恩病评估中可同时关注肠道损伤与功能残疾两个维度。
  • 对适合患者考虑早期(病程前2年内)引入抗TNF以降低肠道损伤评分。

局限性

  • 单中心三级转诊中心研究,结果需进一步专门的前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The notion of Crohn's disease (CD) as a chronic, progressive and disabling condition has led to the development of new indexes: the Lémann Index measuring cumulative bowel damage and the Inflammatory Bowel Disease (IBD) Disability Index, assessing functional disability. AIMS: To measure the Lémann Index and the IBD Disability Index in a large prospective cohort of CD patients and to assess the correlation between these two indexes. METHODS: We performed a prospective study in a tertiary referral centre including all consecutive CD outpatients. We assessed the Lémann Index and the IBD Disability Index questionnaire in all patients. RESULTS: One hundred and thirty CD patients were consecutively included. The mean Lémann Index (±SD) was 11.9 ± 14.1 and ranged from 0 to 72.5 points. Factors associated with a high bowel damage score were: disease duration, anal location, previous intestinal resection, clinical and biological disease activity, exposure to immunosuppressants, and exposure to anti-TNF (P < 0.005). Among patients exposed to anti-TNF, the Lémann Index was lower in those who were exposed in the first 2 years of their disease (P = 0.015). The mean IBD Disability Index was 28.8 ± 6.3 and ranged from 0 to 71 points. The factors associated with high disability score were: female gender, anal location, extra digestive manifestations, clinical and biological disease activity and exposure to anti-TNF (P < 0.005). No correlation was observed between the Lémann Index and IBD Disability Index (P = 0.15). CONCLUSIONS: This is the first study to prospectively evaluate the Lémann Index and the IBD Disability Index in a large cohort of CD patients in a tertiary centre. Early introduction of anti-TNF treatment was associated with lower bowel damage scores, and no correlation was observed between the Lémann Index and the IBD Disability Index. Further dedicated prospective studies are necessary to confirm these results.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lauriot Dit Prevost C, Azahaf M, Nachury M, et al. Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the Lémann Index and Inflammatory Bowel Disease Disability Index. Aliment Pharmacol Ther. 2020. PMID: 32221985. doi:10.1111/apt.15681

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。